Acyclovir-Induced Nephrotoxicity: The Protective Benefit of Curcumin

Year 2021, Volume: 80 Issue: 1, 22 - 28, 15.06.2021

Elias Adıkwu , James Kemelayefa

Abstract

Objective: Nephrotoxicity may decrease the clinical use of acyclovir (ACV). Curcumin (CUM) is used traditionally as treatments for some diseases. This study examined the protective effect of CUM against ACV-induced nephrotoxicity in rats.

Materials and Methods: Forty-five male Wistar rats (240–250g) randomized into nine groups (n=5) were used. Group 1(Placebo control) received water (0.2mL/day) intraperitoneally (i.p) whereas group 2 (Solvent control) received corn oil (0.2mL/day) per oral (p.o) for 7 days. Groups 3-5 received CUM (25, 50 and 100 mg/kg/day p.o) for 7 days. Group 6 received ACV (150 mg/kg/day i.p) for 7 days. Groups 7-9 were pre-treated with CUM (25, 50 and 100 mg/kg/day p.o) before the treatment with ACV (150 mg/kg/day i.p) for 7 days. On day 8, the rats were anesthetized; blood samples were collected and evaluated for serum biochemical indices. The k idneys were weighed and assessed for histology and oxidative stress indices.

Results: ACV produced no significant (p>0.05) effects on the body and kidney weights of rats when compared to control. ACV caused significant (p<0.001) elevations in serum creatinine, urea, uric acid and kidney malondialdehyde levels when compared to control. ACV significantly (p<0.001) decreased kidney glutathione,catalase, glutathione peroxidase, superoxide dismutase, serum total protein, albumin, potassium, chloride, sodium and bicarbonate levels when compared to control. Tubular necrosis and hypercellular glomerulus with mesangial proliferation occurred in the ACV-treated rats. ACV-induced nephrotoxicity was abrogated in a dose-related fashion by CUM 25mg/kg (p<0.05), 50mg/kg (p<0.01) and 100mg/kg (p<0.001) when compared to ACV.

Conclusion: CUM may clinically prevent ACV-induced nephrotoxicity.

Keywords

Acyclovir,, Curcumin,, Kidney,, Toxicity

References

• 1. Klahr S. Nonexcretory Functions of the Kidney. In: Klahr S. (eds) The Kidney and Body Fluids in Health and Disease. Springer, Boston, MA,1983.
• 2. Arunvikram K, Mohanty I, Sardar KK, Palai S, Sahoo G and Patra R.C. Adverse drug reaction and toxicity caused by commonly used antimicrobials in canine practice, Vet World. 2014;7 (5): 299-305.
• 3. Mehta R L, Pascual MT, Soroko S, Savage BR, Himmelfarb J, Ikizler TA, et al. Spectrum of acute renal failure in the intensive care unit: The PICARD experience. Kidney Int. 2004, 66; 1613–1621.
• 4. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, et al. Acute renal failure in critically ill patients: A multinational, multicenter study. JAMA 2005; 294; 813–818.
• 5. Bryson YJ, Dillon M, Lovett M, Acuna G, Taylor S, Cherry JD et al. Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. A randomized double-blind controlled trial in normal subjects. N Engl J Med 1983; 308(16):916-921
• 6. Keeney RE, Kirk LE, Bridgen D. Acyclovir tolerance in humans. Am J Med 1982; 73: 176-181.
• 7. Chou JW, Yong C, Wootton SH. Case 2: Rash, fever and headache first, do no harm. Paed Child Heal. 2008; 13: 49-52.
• 8. Genc G, Ozkaya O, Acikgoz Y, Yapici O, Bek K, Gulnar Sensoy S, et al. Acute renal failure with acyclovir treatment in a child with leukemia. Drug Chem Toxicol 2010; 33: 217-219.
• 9. Bean B, Aeppli D.Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster. J Infect Dis 1985; 151: 362-365.
• 10. Ahmad T, Simmonds M, McIver AG, McGraw ME. Reversible renal failure in renal transplant patients receiving oral acyclovir prophylaxis. Pediatr Nephrol 1994; 8: 489-491
• 11. Vomiero G, Carpenter B, Robb I, Filler G. Combination of ceftriaxone and acyclovir - an underestimated nephrotoxic potential? Pediatr Nephrol 2002; 17: 633-637.
• 12. Lu H, Han Y-J, Xu J-D, Xing W-M, Chen J. Proteomic Characterization of Acyclovir-Induced Nephrotoxicity in a Mouse Model. PLoS ONE. 2014; 9(7):1-6
• 13. Aggarwal B B, Kumar A, Bharti A C, Anticancer potential of curcumin: Preclinical and clinical studies. Anticancer Res. 2003, 23, 363–398
• 14. Gounder DK, Lingmallu J. Comparison of chemical composition and antioxidant potential of volatile oil from fresh dried and cured turmeric (Curcuma longa) rhizomes. Industrial Crops and Products, 2012; 38: 124—131.
• 15. Gupta SC, Patchva S, Aggarwal B B. Therapeutic Roles of Curcumin: Lessons Learned from Clinical Trials. AAPS J. 2013, 15, 195–218
• 16. Hewlings SJ, and Kalman DS Curcumin: A Review of Its’ Effects on Human Health. Foods 2017; 6; 92; 1-11
• 17. Aggarwal B B, Harikumar K B, Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int. J. Biochem. Cell Biol. 2009, 41, 40–59
• 18. El Shemy MA. Protective effects of curcumin against Augmentin-induced hepatotoxicity in rats. Benha Vet Med J. 2018; 35: 1:375-386
• 19. He L, Peng X, Zhu J, Liu G, Chen X, Tang C et al. Protective effects of curcumin on acute gentamicininduced nephrotoxicity in rats. Can. J. Physiol. Pharmacol., 2015, 93(4), 275-282.
• 20. Miriyala S, Panchatcharam M, Rengarajulu P. Cardioprotective effects of curcumin. Adv Exp Med Biol 2007;595:359-77
• 21. Chakraborty M, Bhattacharjee A, and Kamath JV. Cardioprotective effect of curcumin and piperine combination against cyclophosphamide-induced cardiotoxicity. Indian J Pharmacol. 2017; 49(1): 65–70.
• 22. Campos S B, Seguro A C, Cesar KR, Rocha AS. Effects of acyclovir on renal function. Nephron, 1992; 62, 74–79
• 23. Buege JA, Aust SD. Microsomal lipid peroxidation. Meth Enzymol 1978; 52: 302-310.
• 24. Aebi H Catalase in vitro. In Method in Enzymology, Colowick SP and Kaplane NO, Eds.,New York, NY, USA: Academic Press, 1984
• 25. Sun M, Zigman S. AnImprovedSpectrophotometer Assay of Superoxide Dismutase Based On Epinephrine, Antioxidation. Analy Biochem 1978; 90: 81-89
• 26. Sedlak J, Lindsay RH. Estimation of total, protein-bound and non-protein sulfhydryl groups in tissue with Ellman’s reagent. Anal Biochem 1968 ; 25: 192-205.
• 27. Rotruck JT, Rope AL, Ganther HF, Swason AB. Selenium: biochemical role as a component of glutathione peroxidase. Sci 1973; 179: 588–590.
• 28. Izzedine H, Launay-Vacher V, and Deray G. Antiviral drug-induced nephrotoxicity. Am J Kidney Dis 2005; 45: 804-817.
• 29. Agrawal S, Goel RK. Curcumin and its protective and therapeutic uses. Natl J Physiol Pharm Pharmacol 2016;6:1-8.
• 30. Whitley R J, Middlebrooks M, Gnann JW, Jr. Acyclovir: The past ten years. Adv. exp. Med. Biol., 1990; 278, 243–253
• 31. Tucker WE Jr, Macklin AW, Szot RJ, Johnston RE, Elion GB, de Miranda P, et al. Preclinical toxicology studies with acyclovir: Acute and subchronic tests. Fundam. appl Toxicol., 1983b ; 3; 573–578.
• 32. Perazella MA, Crystal-induced acute renal failure, Amer J of Med, 1999; 106 (4) 459–465.
• 33. Dennis JM, Witting PK. Protective Role for Antioxidants in Acute Kidney Disease. Nutr. 2017; 9(7): 718.
• 34. Gaschler MM, Stockwell BR Lipid peroxidation in cell death. Biochem Biophys Res Commun. 2017; 15; 482(3): 419–425
• 35. Tirkey N, Kaur G, Vij G, Chopra K. Curcumin, a diferuloylmethane, attenuates cyclosporine-induced renal dysfunction and oxidative stress in rat kidneys. BMC Pharmacol 2005; 5: 15; 1-10
• 36. Palipoch S, Punsawad C, Chinnapun D, and Suwannalert P. Amelioration of cisplatin-induced nephrotoxicity in rats by curcumin and α-tocopherol. Trop. J. Pharm. Res. 2013;12, 973–979
• 37. Yadav VR, Suresh S, Devi K, Yadav S. Effect of cyclodextrin complexation of curcumin on its solubility and antiangiogenic and anti-inflammatory activity in rat colitis model Journal of the American Asso of Pharm Scie Tech. 2009; 10: 752—762.
• 38. Maheshwari RK, Singh AK. Multiple biological activities of curcumin: a short review Life Sci. 2006; 78: 2081—2087.
• 39. Priyadarsini K I, Maity D K, Naik, G H, Kumar MS, Unnikrishnan M K, Satav JG, et al. Role of phenolic O-H and methylene hydrogen on the free radical reactions and antioxidant activity of curcumin. Free Radic. Biol. Med. 2003, 35, 475–484
• 40. Lin YG, Kunnumakkara AB, Nair A, Merritt WM, Han LY, Armaiz-Pena GN et al. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-κB pathway. Clin. Cancer Res. 2007, 13, 3423–3430.
• 41. Marchiani A, Rozzo C, Fadda A, Delogu G, Ruzza P. Curcumin and curcumin-like molecules: From spice to drugs. Curr. Med. Chem. 2014, 21, 204–222.
• 42. Kohli K, Ali J, Ansari MJ, Raheman Z. Curcumin: A natural antiinflammatory agent Indian J of Pharm 2005; 37: 141—147